🇺🇸 FDA
Pipeline program

zanubrutinib, bendamustine, and obinutuzumab

FL-ZBG-01

Unknown small_molecule active

Quick answer

zanubrutinib, bendamustine, and obinutuzumab for Follicular Lymphoma is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Follicular Lymphoma
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials